Neptune Technologies & Bioressources Announces the Issuance of an Additional Key US Patent
17 November 2011 - 12:00AM
Neptune Technologies and Bioressources Inc. (Nasdaq:NEPT)
(TSX-V:NTB), announces that the U.S. Patent and Trademark Office
(the "USPTO") has issued a new U.S. patent No. 8,057,825 that
protects and provides Neptune with the exclusive use of krill
extracts in the U.S., as a method for reducing cholesterol,
platelet adhesion and plaque formation.
While the previous, recently awarded U.S. patent No. 8,030,348
secured Neptune's intellectual property on a composition of novel
omega-3 phospholipids, which are the main bioactive ingredients in
all krill oils, this new patent grants Neptune protection on
specific cardiovascular health benefits when using krill extracts,
such as reduction of cholesterol, platelet adhesion and plaque
formation.
"With this additional patent, Neptune is the only company
exploiting krill while benefiting from protected intellectual
property and commercialization rights for those cardiovascular
applications. This is another major gain, strengthening our leading
edge in the U.S. market" said Michel Timperio, Vice-President
Business Development. "Competitors and distributors, previously
claiming in the U.S. market these benefits for their krill
extracts, will now be compelled to modify their claims and/or enter
into licensing agreements with Neptune" he added.
"This new patent increases the number of our patents to 78 and
reinforces Neptune's leadership in the krill/omega-3 phospholipids
market. Since its inception, Neptune's focus on intellectual
property and patent protection has always been an integral part of
the strategic action plan of Neptune's management team and a key
component of its vision for value creation" said Henri Harland,
President and CEO. "It is normal ethical business practice not to
infringe on IP protection and a legitimate right and duty to
enforce it when infringed. Even though Neptune remains open to
negotiate commercialization license agreements since these
additional assets enhance our commercial offering, making Neptune a
partner of choice in the nutraceutical and pharmaceutical
industries, Neptune will always stand by its patents and will
continuously enforce them" he stated.
"The issuance of this patent is also a major advantage to
Neptune's subsidiary Acasti Pharma Inc. (Acasti) (TSX-V:APO).
Acasti is focused on bringing to market highly purified forms
omega-3 phospholipids for the treatment of
cardiometabolic/cardiovascular diseases" added Henri Harland.
About Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipids products for the nutraceutical and
pharmaceutical markets. Neptune focuses on growing consumer health
markets, including cardiovascular, inflammatory and neurological
diseases, driven by consumers taking a more proactive approach to
managing health and preventing diseases. Neptune sponsors clinical
trials aimed to demonstrate its product health benefits and to
obtain regulatory approval for label health claims. Neptune is
continuously expanding its intellectual property portfolio as well
as clinical studies and regulatory approvals. Neptune's products
are marketed and distributed in over 20 countries worldwide.
About Acasti Pharma Inc.
Acasti is developing a product portfolio of proprietary novel
long-chain omega-3 phospholipids. Phospholipids are the major
component of cell membranes and are essential for all vital cell
processes. They are one of the principal constituents of High
Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti is focusing initially
on treatments for chronic cardiovascular and cardiometabolic
conditions within the over-the-counter, medical food and
prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm Inc. is pursuing pharmaceutical neurological
applications and a clinical study for a medical food product with a
multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational
partners.
"Neither Nasdaq nor the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release."
Statements in this press release that are not statements of
historical or current fact constitute "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 and Canadian securities laws. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other unknown factors that could cause the
actual results of the Company to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are
urged to consider statements labeled with the terms "believes,"
"belief," "expects," "intends," "anticipates," "will," or
"plans" to be uncertain and forward-looking. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company's reports filed with the Securities and Exchange Commission
and the Canadian securities commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Dave Burwell
(888) 221-0915
dabe@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024